Evaluation of safety, side effects and how the inhaled drug CHF10073 is absorbed, modified and removed from the body when administered alone or in combination with itraconazole in male and female healthy adults
CLI-010073AA1-01
Phase 1 other active
Quick answer
Evaluation of safety, side effects and how the inhaled drug CHF10073 is absorbed, modified and removed from the body when administered alone or in combination with itraconazole in male and female healthy adults for Pulmonary fibrosis is a Phase 1 program (other) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chiesi Farmaceutici S.p.A
- Indication
- Pulmonary fibrosis
- Phase
- Phase 1
- Modality
- other
- Status
- active